• 出版社/出版日：Mordor Intelligence / 2020年4月
|Single User||￥459,000 (USD4,250)||▷ お問い合わせ|
|Team User||￥513,000 (USD4,750)||▷ お問い合わせ|
|Corporate License||￥810,000 (USD7,500)||▷ お問い合わせ|
The Transdermal Skin Patches market is projected to grow with a CAGR of 4.2% over the forecast period. The major factor attributing to the growth of the market is the increasing advantages of transdermal medicine over the oral and ingesting medications, like preventing gastrointestinal toxicity that result in nausea and vomiting, and as they are non- invasive in nature, they lower the inconvenience caused due to intravenous or parenteral therapies. The major advantage is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. Furthermore, increasing funding and investments for drug development boosts the market growth. However, the inability of the skin to absorb a range of active substances constraints the market growth.
Key Market Trends
Smoking Reduction and Cessation Aid Segment is Expected to Grow at High CAGR in the Forecast Period.
The growth rate of the segment is attributed to a large number of smokers globally, and increasing awareness of the advantages of the transdermal route of administration of drugs for smoking cessation. According to the World Health Organization, 8 million people die every year due to smoking. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. According to the Centers for Disease Control and Prevention, in 2018, nearly 14 of every 100 U.S. adults aged 18 years or older currently smoke cigarettes, which means a predictable 34.2 million adults in the United States currently smoke cigarettes. More than 16 million Americans live with a smoking-related disease. With the increasing pool of smokers and increasing people quitting, the rate of growth of the segment is ought to increase.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players and established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. In this region, the United States has the maximum share due to supportive healthcare policies, the high number of patients, and a developed healthcare market. Technologies supporting transdermal patches are being enhanced uninterruptedly to make them more versatile and effective, in the United States.
The transdermal skin patches market is moderately competitive and consists of several international companies. The major players are focused on the adoption of various strategies such as product innovation, product launches, and approvals, R&D investment for advancements in transdermal patches, merger and acquisition as their developmental strategies to sustain the competitive environment in the market. Some of the companies which are currently gaining attention in the market are Teva Pharmaceuticals USA, Inc., Novartis AG, Teikoku Pharma USA, Inc, Mylan Inc., 3M, Luye Pharma Group, Purdue Pharma Manufacturing L.P., Henan Lingrui Pharmaceutical Ltd., Mundipharma.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Advantages of Transdermal Medicine Over the Oral and Ingesting Medications
4.2.2 Increasing Funding and Investments in Drug Research
4.3 Market Restraints
4.3.1 Inability of the Skin to Absorb a Range of Active Substance
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Single-layer Drug-in-Adhesive
5.1.2 Multi-layer Drug-in-Adhesive
5.2 By Application
5.2.1 Pain Relief
5.2.2 Smoking Reduction and Cessation Aid
5.2.3 Overactive Bladder
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Teva Pharmaceuticals USA, Inc.
6.1.2 Novartis Pharmaceuticals Corporation
6.1.3 Teikoku Pharma USA, Inc
6.1.4 Mylan Inc.
6.1.6 Luye Pharma Group
6.1.7 Purdue Pharma Manufacturing L.P.
6.1.8 Henan Lingrui Pharmaceutical Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
• 英文レポート名：Transdermal Skin Patches Market - Growth, Trends, and Forecast (2020 – 2025)
• 日本語訳：世界の経皮パッチ市場 2020年-2025年
• レポートコード：D0-MOR-AP1162 ▷ お問い合わせ（見積依頼・ご注文・質問）